Westlake and Ascend close plants, Chemify opens AI-robotics lab, Formation licenses gusacitinib to Sanofi, and more ...

New York-based Formation Bio, an AI-native pharma company focused on accelerating drug development, revealed that its ...

The star of Monday’s deal is gusacitinib, a small-molecule drug that Formation is developing for chronic hand eczema. Sanofi ...

Having secured one of last year’s largest funding rounds, AI-focused Formation Bio is now eyeing up 545 million euros ($626 ...

Formation Bio’s subsidiary, Libertas Bio, has licensed gusacitinib, an oral dual JAK/SYK inhibitor, to Sanofi.

REDWOOD CITY, CA, USA I June 11, 2025 I Juvena Therapeutics, Inc. (“Juvena”), a clinical-stage biotechnology company pioneering tissue restorative biologics for chronic muscle and metabolic diseases, ...

TORONTO (AP) — U.S. President Donald Trump will arrive Sunday for a Group of Seven summit in a country he has suggested should be annexed and as he wages a ...

LUND, Sweden and INDIANAPOLIS, IN, USA I June 3, 2025 I Camurus (NASDAQ STO: CAMX) and Eli Lilly and Company (“Lilly”) have entered a collaboration and license agreement, granting Lilly exclusive, ...

Sanofi licenses gusacitinib from Formation Bio. 24 June 2025. Biotechnology. Datroway first US-approved TROP2-directed therapy in lung cancer. 24 June 2025. Company Spotlight. A global ...

Itepekimab met the primary endpoint in one of two COPD phase 3 studies AERIFY-1 study met its primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former ...

Beyfortus public health advantage bolstered by first real-world comparison of infant vs maternal RSV immunization programs Late-breaking data show infant respiratory syncytial virus (RSV ...